Raft Pharmaceuticals is a startup biopharmaceutical company developing novel therapy targeting lipid rafts in inflamed and activated cells. Raft’s product, recombinant protein RFT-001 regulates cholesterol trafficking in the plasma membrane and normalizes clustered and cholesterol-overloaded lipid raft microdomains – specifically in inflamed glia and macrophages, relevant to the development of chronic pain states. Chronic pain is a major health problem affecting 20% of the population and 40% of older adults, having an extraordinary negative impact on quality of life. The annual cost of chronic pain is $635B. Opiates, NSAIDs, and anticonvulsants relieve pain for short intervals, but are less effective for chronic therapy, have serious side effects and potential for diversion and addiction (opioid epidemics). Animal testing shows the unprecedented efficacy of RFT-001 in models of chemotherapy- and nerve injury-induced neuropathic pain, as well as migraine.
Company Details
- Founded
- -
- Address
- 10225 Barnes Canyon Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://raftpharma.com
- HQ
- San Diego, California
Raft Pharmaceuticals Questions
Raft Pharmaceuticals's website is https://raftpharma.com
Raft Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/raftpharma
Raft Pharmaceuticals's industry is
Biotechnology Research
Raft Pharmaceuticals's top competitors are
Mountain View Pharmaceuticals, Inc.,
Inspira Pharmaceuticals Limited,
Tyna Pharmaceuticals Inc.,
Rich Pharmaceuticals, Inc.,
Inflexion Pharmaceuticals Llc,
Ernest Pharmaceuticals,
Sacyl Pharmaceuticals, Inc.,
Arya Pharmaceuticals,
Nelson Pharmaceuticals, Llc,
Millenium Pharmaceuticals.
Raft Pharmaceuticals's categories are Biotechnology Research
Raft Pharmaceuticals's founding year is 2018
